Kaschin-Beck disease
Conditions
Interventions
Zhengqing Fengtongning sustained release tablet group:Oral Zhengqing Fengtongning sustained-release tablet, 60mg/ time, twice/day, after meals, for 3 months
Etocoximab group:Oral etocoxib tablets, 30mg/ time, twice/day, after meals, for 3 months
Sponsors
The Second Affiliated Hospital of Shaanxi University of Chinese Medicine
Eligibility
Sex/Gender
All
Age
40 Years to 65 Years
Inclusion criteria
Inclusion criteria: ? It meets the diagnostic criteria of KBD in Western medicine; ? It meets the standard of spleen-kidney-yang deficiency and cold-dampness-blocking collateral-type of KBD; ?Age 40-65 years old, gender is not limited; ? have been diagnosed with KBD in local medical institutions; ?Voluntarily receive randomized treatment for 3 months, and can complete the efficacy evaluation for 1 month, 3 months and 6 months of treatment; ? Volunteer to take the test and sign the informed consent.
Exclusion criteria
Exclusion criteria: ? Under 40 years old, 65 years old and above; ? Patients who received arthroscopic treatment, joint replacement and other surgical treatment during the observation period; ? Patients with cardiovascular, cerebrovascular, liver, kidney, digestive, blood system, endocrine system and other serious primary diseases and mental disorders; ? Patients with bone tumor, bone tuberculosis and non-specific inflammation; ? Lactating women and pregnant women or allergic to this medicine; ? Can not adhere to the treatment or cooperate with the efficacy of the interviewer
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Visual analogue pain score;Health Status Questionnaire (SF-36 Scale);Gastrointestinal Symptom Grading Scale (GSRS);Joint dysfunction index score (according to WS/T 79-2011 "Kashin-Beck Disease Treatment Effect Evaluation");TNF-a;IL-1ß;Tinetti Balance and Gait Analysis; | — |
Countries
China
Contacts
Public ContactKou jiushe
The Second Affiliated Hospital of Shaanxi University of Chinese Medicine
Outcome results
None listed